Background: Current guidelines recommend a duration of 24 weeks of treatment with pegylated interferon and ribavirin for patients infected with chronic hepatitis C virus (HCV) genotypes 2 and 3. Several trials investigated whether shorter treatment duration is equally effective in achieving sustained virological response (SVR). Our aim was to determine the optimal length of treatment in patients with HCV genotypes 2 and 3. Methods: Systematic literature identified eight randomized controlled trials (RCTs). Meta-analyses were carried out on SVR data from three studies randomized at baseline and five studies randomized at rapid virological response (RVR) to either 12-16 weeks or a 24-week course. The current treatment guidelines for patients infected with HCV genotypes 2 and 3 is pegylated interferonα2a in combination with 800 mg ribavirin or pegylated interferon-α2b in combination with weight-based ribavirin for 24 weeks [2, 3] . Approximately 80% of patients achieve sustained virological response (SVR) with this regimen [4] . However, side effects are common and their frequency increases with the length of treatment. This and economic consideration favour shorter treatment duration [5, 6] . A number of ongoing clinical trials have been trying to identify the optimal length of therapy, safety profiles and cost-effectiveness for the treatment of these patients, but have yielded discordant results [7] .
Background: Current guidelines recommend a duration of 24 weeks of treatment with pegylated interferon and ribavirin for patients infected with chronic hepatitis C virus (HCV) genotypes 2 and 3. Several trials investigated whether shorter treatment duration is equally effective in achieving sustained virological response (SVR). Our aim was to determine the optimal length of treatment in patients with HCV genotypes 2 and 3. Methods: Systematic literature identified eight randomized controlled trials (RCTs). Meta-analyses were carried out on SVR data from three studies randomized at baseline and five studies randomized at rapid virological response (RVR) to either 12-16 weeks or a 24-week course.
Results: Pooled SVR data were higher in standard treatment in RCTs that randomized at baseline, with a relative risk (RR) of 0.88 (95% confidence interval [CI] 0.76-1.01). The pooled proportion of SVR rates of RCTs that randomized at RVR were similar in the short treatment group (82%) as in the standard treatment (83%), with the pooled effect given by a RR of 1.00 (95% CI 0.92-1.09). Conclusions: A shorter course (12-16 weeks) of combination therapy does not impair efficacy compared with a 24-week course in HCV genotypes 2 and 3 patients who achieve an RVR. HCV patients without RVR should consider 24 weeks of treatment.
Chronic infection with hepatitis C virus (HCV) affects approximately 170-180 million patients worldwide and is one of the main causes of chronic liver disease and liver transplantation in the US and in Europe [1] .
The current treatment guidelines for patients infected with HCV genotypes 2 and 3 is pegylated interferonα2a in combination with 800 mg ribavirin or pegylated interferon-α2b in combination with weight-based ribavirin for 24 weeks [2, 3] . Approximately 80% of patients achieve sustained virological response (SVR) with this regimen [4] . However, side effects are common and their frequency increases with the length of treatment. This and economic consideration favour shorter treatment duration [5, 6] . A number of ongoing clinical trials have been trying to identify the optimal length of therapy, safety profiles and cost-effectiveness for the treatment of these patients, but have yielded discordant results [7] .
The largest trial to date (the ACCElERATE trial) described significantly lower SVR rates with 16 weeks of therapy in comparison with 24 weeks, even in patients who achieved rapid virological response (RVR) after 4 weeks of therapy [6] . By contrast, other studies have demonstrated that therapeutic success of a treatment course of 12-16 weeks as compared with 24 weeks is similar in patients who achieve an RVR [8] [9] [10] [11] .
Although these trials document that abbreviated HCV therapy might serve as a viable option, it remains unclear whether this holds for all HCV genotype 2 or 3 patients under all circumstances. It is paramount to obtain a better estimate of the treatment effect in order to judge which patients benefit from further treatment refinements. Pooling data from the individual trials in a formal meta-analysis greatly increases statistical power and enables us to address this issue.
Recently, a meta-analysis compared standard and shorter treatment and concluded that 24 weeks should remain the standard treatment duration for HCV genotype 2, high viraemic HCV genotype 3, and patients without an RVR might achieve improved SVR rates with longer treatment than the recommended 24 weeks [12] . However, this meta-analysis aimed to analyse the effect of genotype (2 or 3) on SVR data. In addition, the authors performed a meta-analysis
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Optimal length of antiviral therapy in patients with hepatitis C virus genotypes 2 and 3: a meta-analysis Introduction to establish which duration of treatment would serve well in genotypes 2 and 3. In the second meta-analysis, the authors did not include all current studies that were available, and study designs and randomization points were different. For example, two trials randomized at RVR, whereas one trial randomized at baseline [6, 10, 11] . Andriulli et al. [13] pooled SVR data from a Norwegian and an Italian study [14] . The Norwegian study was a non-randomized pilot study and the Italian study was randomized at baseline [13, 14] .
The purpose of this study is to systematically analyse all randomized controlled trials (RCTs) that compare short (12-16 weeks) versus standard (24 weeks) duration in HCV genotypes 2 and 3, in order to assess the relative efficacy of each arm.
Methods
We followed the QUORUM guidelines for all steps reported in this meta-analysis [15] . ' were combined ( Figure 1 ). Our search was limited to human adult randomized clinical trials that were published in English literature.
Literature search

Study selection
We included prospective studies that evaluated standard pegylated interferon and ribavirin combination therapy in HCV genotypes 2 and 3 patients and compared short (12-16 weeks) with standard (24 weeks) treatment duration. We adopted the following inclusion criteria: manuscripts written in English, patients with HCV genotype 2 or 3, use of standard combination therapy similar in both arms, randomized double-blind trials, availability of SVR rates in both arms, and the report was published in a book, journal, proceeding or indexed abstraction.
Exclusion criteria were studies referring to patients with HIV coinfection, hepatitis B virus coinfection, decompensated liver cirrhosis, hepatocellular carcinoma, haemophilia, and liver or renal transplantation. Studies that involved previously treated patients, nonresponders or relapsers were excluded.
Validity assessment
The quality of the RCTs was assessed and scored using the Jadad scale, which considers three items: randomization (1 point if yes or 2 points if the method to generate the sequence of randomization was described and appropriate), double blinding (1 point if yes or 2 points if the method of double blinding was described and appropriate) and description of withdrawals and dropouts (1 point) [16] . Maximal scoring for the RCTs in this metaanalysis was 3 points. All studies were RCTs and open label. One study was double blind until 16 weeks of treatment [6] . All studies described their dropouts. It was not possible to assess quality of the abstracts because we did not have access to a peer-review; therefore, a secondary meta-analysis was carried out without the abstracts.
Data abstraction
Titles and abstracts of all retrieved records and subsequently full-text articles were examined independently by two investigators (SS and IW) to identify RCTs that satisfied the inclusion criteria. Discrepancies in selection were resolved by discussion between authors of this meta-analysis.
All data from the selected studies were extracted using a standardized data collection form. The following characteristics were recorded: the first author's name, year of publication, study design, funding by pharmaceutical company, full text and population (gender, ethnicity, age, body mass index, fibrosis stage and HCV viral load).
Data were separated and extracted for short and standard treatment regarding the following: number of participants, duration of treatment, dosages and type of pegylated interferon and ribavirin, RVR, end of treatment (EOT) and SVR. In case of missing variables, we contacted the authors of the individual studies to obtain additional data.
End points of interest
The primary outcome of interest in this meta-analysis was to explore SVR rates of the RCTs. SVR is defined as a negative result on a qualitative PCR assay for HCV RNA 6 months after the EOT. Secondary end points included RVR, defined as a negative result on a qualitative PCR assay for HCV RNA 4 weeks after the start of treatment, and EOT, defined as a negative result on a qualitative PCR assay for HCV RNA after termination of treatment (short [12-16 weeks] versus standard [24 weeks]). The number needed to treat is calculated as 1 divided by the absolute risk reduction.
Statistical analyses
The effect of the two management strategies on SVR rates in HCV genotype 2 or 3 patients was expressed as a pooled relative risk (RR) with a 95% confidence interval (CI). Outcomes were analysed on an intentionto-treat basis. All data were pooled using a random effect model. Funnel plots of individual study results were created by plotting the RRs against sample size to detect asymmetry in the distribution of trials.
All statistical analyses were performed using Review Manager version 5.0.16 for Windows (provided by the Cochrane Collaboration, Copenhagen, Denmark).
The presence of a publication bias was assessed on the basis of a funnel plot for asymmetry. For formal statistical testing, we used a regression asymmetry test to obtain the degree of funnel plot asymmetry as measured by the intercept from regression of standard normal deviates against precision, both after log transformation.
Results
Trial characteristics
Our search identified 8 potential RCTs representing a total of 2,786 HCV genotype 2 or 3 patients. A total of five RCTs were published as full papers [6, [9] [10] [11] 17] and the remaining three studies in abstract form [18] [19] [20] . The selection of articles is depicted in Figure 2 .
The trial by Mangia et al. [8] did not meet the inclusion criteria in our meta-analysis, as stratification was different in randomization. Randomization in the variable duration group was not performed; patients with RVR were treated for 12 weeks and those without RVR were treated for 24 weeks [8] .
Included RCTs had two different study designs. We identified RCTs that randomized at baseline (entry) of the study [6, 9, 17] and RCTs that randomized to short and standard treatment after achieving RVR [10, 11, [18] [19] [20] . For homogeneity of effect measures across the included studies, we performed two separate meta-analyses for both randomization moments to reflect our primary end point, SVR. One study published only SVR rates in short versus standard therapy and was limited to HCV genotype 2 patients [17] . Characteristics of the eight studies and corresponding study populations are given in Tables 1 and 2 .
The standard duration of treatment was 24 weeks for all studies. By contrast, the definition of 'short duration' differed among trials: three trials defined short 
Figure 2. Selection of articles
treatment duration as 16 weeks [6, 11, 17] , one trial as 14 weeks [10] and four trials as 12 weeks of treatment [9, [18] [19] [20] , respectively. For the benefit of this study, we analysed these various shorter lengths collectively, which showed no difference in achieving SVR. Pegylated interferon-α2a [6, 9, 11, 16, 18] of 180 µg/ week was given in five studies, two studies used pegylated interferon-α2b of 1.5 µg/kg/week [10, 12] and one study used interferon 3 MIU thrice weekly [18] .
Ribavirin was administered daily at a dosage depending on body weight of 800-1,400 mg daily in six trials [10, 11, [17] [18] [19] [20] and at a fixed dose of 800 mg daily in 2 trials [6, 9] .
Meta-analysis of SVR rates after randomization at baseline
The sample size weighted pooled proportion of SVR in standard (24 weeks) treatment was 74% compared with 63% in short (12-16 weeks) treatment. Pooled RVR rates after randomization at baseline in standard treatment was 63% versus 64% in short treatment.
For the standard duration groups, SVR rates among three RCTs ranged from 70% to 95% [6, 9, 17] , and the highest success rate was found in the study that was restricted to patients with HCV genotype 2 infection [17] . SVR rates among short (12-16 weeks) duration trials ranged from 59% to 94% [6, 9, 17] .
Two large trials with a total of 1,851 patients favoured standard (24 weeks) treatment with an RR of 0.75 (95% CI 0.65-0.86) and 0.88 (95% CI 0.82-0.95) [6, 9] . A third trial studying 150 patients supports equal efficacy with an RR of 0.99 (95% CI 0.91-1.08) [17] .
Pooling of the collective data, revealed that SVR rates were consistently higher in patients who received 24 weeks of treatment with an RR of 0.88 (95% CI 0.76-1.01; Figure 3) . None of the trials produced significantly different rates, whereas the test for funnel plot asymmetry was not significant (Figure 4 ).
We then searched for reasons why shorter treatment apparently fails to benefit these patients and focused on the EOT response. Sample-size-weighted pooled proportion of EOT in standard treatment was 89% versus 93% in short treatment. Short treatment had a comparable EOT with the standard treatment group, showing a pooled RR of 1.05 (95% CI 1.02-1.08). We found that a higher proportion of patients in the short therapy group relapsed relative to standard treatment (37% versus 26%) [6, 9, 17] .
The failure to detect an advantage of shorter treatment duration was not the result of an imbalance in the percentages of patients achieving RVR, which was comparable in both groups with a pooled RR of 1.04 (95% CI 0.98-1.11).
Subanalysis of only HCV genotype 2 or 3 patients in trials randomized at baseline showed an advantage of standard treatment with a pooled RR of 0.85 (95% CI 0.69-1.05) for genotype 2 and 0.88 (95% CI 0.64-1.19) for genotype 3 ( Figures 5 and 6 ).
Meta-analysis of SVR rates in patients with RVR at 4 weeks SVR rates ranging from 79% to 91% for the standard duration group was similar to that of the short duration treatment, which ranged from 81% to 90%, with a sample-size-weighted pooled proportion of SVR of 83% in the standard treatment comparable with 82% in the short treatment group [10, 11, [18] [19] [20] .
All studies randomized patients at RVR, and the majority favoured short therapy. RR ranged from 0.89 to 1.14 [11, [18] [19] [20] . In odds with these findings, another study on 298 patients favoured standard treatment duration, with a RR of 0.89 (95% CI 0.81-0.98) [10] . Therefore, the pooled effect suggested that shorter treatment is not different in efficacy compared with standard treatment in genotype 2 or 3 patients who achieve RVR by 4 weeks (RR of 1.00 [95% CI 0.92 -1.09]; Figure 7 ). This pooled effect was not different (RR of 1.00 [95% CI 0.89-1.12]) when it was analysed excluding the study that used conventional interferon in combination with ribavirin instead of pegylated interferon combination therapy [18] . Furthermore, pooling the SVR data of randomization at RVR including only full-text papers showed no statistically significant difference on effect of short versus standard treatment (RR 0.94 [95% CI 0.83-1.06]; Figure 8 ) No original trial produced significantly different rates, whereas the test for funnel plot asymmetry was non-significant ( Figure 9) .
EOT rates obtained from three trials were comparable in the standard group versus the short group with ranges from 76% to 96% and 87% to 94% in standard versus short treatment, respectively. The sample-size-weighted pooled proportion of 89% in standard treatment compared with 91% in short treatment [10, 11, 19] . Short treatment did have a comparable EOT with the standard treatment group, showing a pooled RR of 1.03 (95% CI 0.97-1.09). The overall relapse rate in the short treatment group was 18% compared with 17% in the 24 weeks of therapy. Subanalysis of only HCV genotype 2 or 3 patients in trials randomized at RVR suggest no statistically significant difference in short versus standard treatment, with a pooled RR of 0.98 (95% CI 0.89-1.07) and 0.92 (95% CI 0.80-1.05), respectively (Figures 10 and 11) .
The number needed to treat in this group was 94, which means that 94 patients should be treated and would achieve RVR with standard 24 weeks of treatment in order to obtain one more patient achieving SVR compared with short treatment.
Discussion
The results of our meta-analysis of RCTs shows that in HCV genotype 2 or 3 patients who obtain RVR at 4 weeks are most likely to benefit from a shorter therapy of (12-16 weeks) as our meta-analysis shows that both treatment durations are not different in efficacy. Trials that randomized patients at baseline favour standard therapy. These results are likely a result of the proportion of patients who fail to achieve RVR at 4 weeks therapy and relapse after end of shorter therapy.
To put these data into perspective, we calculated the number needed to treat, which implicated that 94 patients should be treated and would achieve RVR with standard 24 weeks of treatment in order to obtain one more patient achieving SVR compared with short treatment.
The results are in line with those obtained by Andriulli et al. [12] . In that study, pooled SVR rates of HCV patients who achieved RVR showed that short or and standard treatment yield similar cure rates. RVR was the most discriminative factor, as patients who did not achieve RVR were more likely to fail with a shorter therapy (odds ratio 2.06 [95% CI 1.40-3.02]). However, they compared a mix of studies with different study designs, including RCTs, an open-label historical control study and results from a retrospective study. In addition, comparison was made among studies that differ in their randomization points of assigning patients in shorter or standard treatment. We focused only on well designed RCTs because they are less susceptible to confounding, and we performed two meta-analyses for the different randomization points. Figure 8 . Forest plot of sustained virological response after short versus standard hepatitis C virus therapy trials that randomized at rapid virological response without abstracts
Apart from RVR, it is possible that there are other (non-)virological factors, such as baseline characteristics including ethnicity, gender and liver histology, as well as ribavirin dosages that might also contribute to the therapeutic success of shorter therapy.
SVR rates were higher in most European and Asian studies in comparison with the ACCElERATE trial and those from the NORDynamIC study group [6, 9] . The HCV population included in Dalgard et al. [10] and von Wagner et al. [11] were relatively younger with mostly early stage fibrosis, whereas 25% of patients in ACCElERATE and 53% of patients in the NORDynamIC group had bridging fibrosis or cirrhosis. Different classification systems were used to stage fibrosis (for example, Metavir, Ishak and APRI scores); therefore, we could not perform a multivariate analysis to determine whether fibrosis stage influenced SVR in this meta-analysis. SVR rates were the highest in the study of Yu et al., [17] and there might be a few reasons for this difference. First, they included only HCV genotype 2 Taiwanese patients. Racial factors have been shown to influence the virological response even when standard treatment is given [21, 22] . Second, the mean body weight was lower. Higher average doses of pegylated interferon or ribavirin per kg body weight contribute to a higher SVR [4, 23, 24] .
A previous study showed that there was no significant difference in SVR rates in HCV genotypes 2 and 3 patients for 24 weeks (or 48 weeks) with 800 mg/ day or 1,000/1,200 mg/day ribavirin [4] . This suggests that the dose of ribavirin is less important for genotypes 2 and 3 compared with 1 and 4.
In our meta-analysis, we found that RCTs with weightbased dosages (800-1,400 mg daily) [10, 11, [17] [18] [19] [20] achieved higher SVR compared with fixed-dose (800 mg daily) [6, 9] . This suggests that there might be a benefit, as higher ribavirin exposure contributes to higher SVR rates and lower relapse rates in shortened treatment regimes in patients.
Furthermore, two types of pegylated interferon (α2a and α2b) were used in these studies. Eight RCTs used pegylated interferon-α2a and two trials used α2b, this might have had an influence on achieving SVR; however, there is little evidence to support the notion that one pegylated interferon is more effective than the other [25] . One abstract used conventional interferon in combination with ribavirin, which might lead to a lower SVR [18] . However, we performed a subanalysis that showed no difference in outcome.
The duration of treatment in the abbreviated regimen varied across trials from 12 to 16 weeks. No difference in SVR was found between these weeks. Recently, an 8-week regimen of antiviral therapy has been investigated and yielded a very high relapse rate (67%) indicating the limitation of reduction of treatment below 12 weeks in patients with HCV genotype 2 who achieved RVR [26] . Our meta-analysis has several limitations. First, we included three trials published as abstracts; therefore, we did not have complete data [18] [19] [20] . Often, abstracts contain preliminary data and use efficacy analysis rather than intention-to-treat analysis to calculate outcomes. This approach can lead to overestimating a treatment effect. Another aspect is that we could not judge their methods and analyses because of the missing explaining text. However, exclusion of abstracts from the analysis did not affect the results.
Second, we included only RCTs in our analysis. Although well designed RCTs are less susceptible to bias than other study designs, generalizability to realworld practice is often limited.
Third, these RCTs are not completely homogenous and might differ in baseline characteristics. We did not have access to individual patient data; therefore, we were unable to analyse potentially important predictors of outcomes such as body mass index, race and severity of baseline disease. Because of randomization, we surmise that there are no differences in both intervention groups.
Fourth, the use different viral load cutoff levels for RVR and EOT among studies is a potential caveat. Cutoff values varied from <600 IU/ml, <50 IU/ml and <15 IU/ml and this could potentially affect the number of patients achieving RVR [9, 11] . However, no effect was measured on SVR in this study [9] .
Finally, as with all meta-analyses, this study has the potential limitation of publication bias. Negative results sometimes fail to be published. However, our data suggest that this does not play a role. The corresponding funnel plot is shown in Figure 4 .
Despite these potential limitations, our analysis provides important information for clinicians treating these patients and suggests that RVR is an important parameter in determining success of shorter therapy. This is underlined with the results by a large RCT by Mangia et al. [8] , which also concluded that a shorter course of therapy (12 weeks) is as effective as a 24-week course for patients with HCV genotype 2 or 3 who have an RVR. This trial did not meet the inclusion criteria in our meta-analysis, as it lacked randomization for the variable duration group; patients with RVR were treated for 12 weeks and without RVR were treated for 24 weeks.
Abbreviated regimens are less expensive, reduce exposure to side effects and might have tolerability advantages over a 24-week regimen. Shorter treatment duration can, in particular, reduce the incidence of delayed, mainly psychiatric, side effects. Moreover, compliance will be improved and there will be fewer drop-out patients because of adverse events when using shorter therapy.
In conclusion, this study shows that for HCV genotype 2 and 3 patients achieving RVR at week 4, the efficacy of a shorter (12-16 weeks) treatment with pegylated interferon and ribavirin is not different from 24 weeks. Patients who do not achieve RVR at week 4 should receive at least 24 weeks of treatment. 
